Bayer will present new data from the ARANOTE trial evaluating ultra-low prostate-specific antigen responses with NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) Efficacy and safety ...

(UroToday.com) The 2025 EAU annual meeting featured a game changer session and a discussant presentation by Dr. Geraldine Pignot. Dr. Pignot discussed Dr. Catto’s presentation “NIAGARA - Surgical ...

Bladder cancer (BLCA) management presents complex clinical challenges requiring deep knowledge of current guidelines and clinical expertise. A recent study by Li et al. evaluated the performance of ...

Focal therapy (FT) has quickly emerged over the last few decades as a prostate cancer (CaP) treatment option due to the growing research indicating more favorable side effects compared to radical ...

Background/Objectives: Prostate cancer (PCa) is a leading cause of cancer-related deaths among men, with early detection playing a crucial role in improving outcomes. MyProstateScore 2.0 (MPS2), a ...

To compare outcomes of nephrectomy for left-sided (n = 70) vs right-sided (n = 118) renal tumours with caval thrombi. In this retrospective analysis (June 2008-February 2023), we evaluated ...

Tumours arising within the developing kidney of children vary widely in their histological appearance and outcome; optimal therapy requires accurate classification and staging. The two major ...

Prostate cancer (PCa) remains the most prevalent cancer among men and the second leading cause of cancer-related deaths worldwide. Early diagnosis is crucial as it opens up various treatment options ...

Background: Gleason score (GS) 10 prostate cancer (PC) is a highly aggressive localized disease. Despite advances in treating high-risk PC, the clinical outcomes and molecular underpinnings of GS 10 ...

One of the clearest examples of an acquired somatic mutation is androgen receptor (AR) amplifications in prostate cancers that have been treated with androgen deprivation therapy (ADT). 1,2 ...